Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
3.760
+0.140 (3.87%)
Jun 27, 2025, 4:00 PM - Market closed
Perspective Therapeutics Employees
As of December 31, 2024, Perspective Therapeutics had 140 total employees, including 138 full-time and 2 part-time employees. The number of employees increased by 21 or 17.65% compared to the previous year.
Employees
140
Change (1Y)
21
Growth (1Y)
17.65%
Revenue / Employee
$10,507
Profits / Employee
-$608,371
Market Cap
279.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CATX News
- 7 days ago - Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - GlobeNewsWire
- 7 days ago - Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - GlobeNewsWire
- 2 months ago - Perspective Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - GlobeNewsWire